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Results: There are currently 24 agents in 36 trials in phase III of AD drug development. Seven of
these 24 agents are symptomatic cognitive-enhancing compounds, and 17 are disease-modifying
treatments (DMTs). Most DMTs address amyloid-related targets (76%). There are 45 agents in phase
II being assessed in 52 clinical trials. Phase II trials include 30 DMTs, with 26 small molecules and 4
immunotherapies. There are 24 agents in the first phase of AD drug development.
Discussion: Amyloid is the principal target of late-stage development programs. There are relatively
few agents in clinical trials for AD suggesting a need to amplify the drug discovery ecosystem.
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by 2050 if treatments are not found [1,2].
New therapies are needed for this burgeoning popula-
tion of affected and at-risk persons that improve the symp-
toms of patients with memory and cognitive decline,
prevent or delay the onset of AD in individuals who are
at-risk for the disease, or slow progression in those with
declining cognition. New therapies are being assessed in
clinical trials but the success rate of AD drug development
has been low with the last new novel agent approved in
2003 [3].
To gain insight into the current AD treatment pipeline, we
reviewed all trials registered in clinicaltrials.gov (accessed
1/4/2016), the US government website that lists all US and
most global clinical trials. Registration of new trials on the
site is required for trials approved by the US Food and
Drug Administration (FDA) since 2007 [4]. We reviewed
this comprehensive website for all agents in clinical trials
for AD dividing them into those in phase I, phase II, and
phase III. The purpose of the study was to understand the
landscape of AD drug development and determineimer’s Association. This is an open access article under the CC BY-NC-ND
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cal practices. The goal is to assess the state of AD drug
development, anticipate the emergence of new therapies, re-
view emerging pharmacologic mechanisms and clinical trial
approaches, and derive lessons possibly helpful in the drug
development process.1. Methods
We interrogated clinicaltrials.gov with the information
summarized here accessed on January 4, 2016. We used
the search features of the site to capture all agents listed
for AD in phase I, II, and III. We captured the trial title,
beginning date, anticipated ending date, anticipated dura-
tion, number of subjects to be enrolled, number of arms
of the study (usually a placebo arm and one or more treat-
ment arms with different doses of the test agent), whether a
biomarker was described, and whether the sponsor was a
biopharma company, the National Institutes of Health
(NIH), a combination of biopharma and NIH, or “other.”
We included trials that were recruiting, active but not re-
cruiting—trials that have completed recruiting and are
continuing as the efficacy or safety of the agent is being
determined—and enrolling by invitation. We did not
include trials listed as not yet recruiting, completed, termi-
nated, suspended, or withdrawn. These exclusions were
based on our interest in the currently active pipeline and
what agents could evolve in the near term. Reasons for ter-
minating, suspending, or withdrawing trials are often not
provided, and we could not draw conclusions about these
trials or the agents involved. The agents and trials reviewed
comprise a comprehensive list of agents currently in trials.
The list is not exhaustive because not all non-US trials are
registered on clinicaltrials.gov, and there is sometimes a
delay in registering trials. The mechanism of action of
each agent was determined from the information on
clinicaltrials.gov (e.g., the mechanism is often noted in
the title of the trial or in a description of the trial) or
from a comprehensive search of the literature if the mech-
anism was not provided on the federal website. In a few
cases, the mechanism is undisclosed. We grouped the mech-
anisms into symptomatic or disease modifying. We further
divided the symptomatic agents into those that were puta-
tive cognitive-enhancing agents or those that addressed
neuropsychiatric symptoms. Disease-modifying therapies
(DMT) were divided into those that targeted amyloid-
related targets, those that aimed at modifying tau-related
mechanisms and those with “other” mechanisms such as
neuroprotection or metabolic effects [5]. The definitions
of disease-modification and neuroprotection are controver-
sial and evolving [6,7]; the terminology is used here to
conveniently classify the types of mechanisms for agents
in current AD drug-development programs. We did not
include nonpharmacologic therapeutic approaches such as
devices, cognitive therapies, and medical foods.2. Results
There are currently 93 agents in some phase of drug
development for AD. Fig. 1 provides a comprehensive over-
view of the agents currently in clinical trials for AD.
2.1. Phase III
There are 24 agents in 36 trials in phase III of AD drug
development. Eight agents are in two or more clinical trials.
Of the agents in trials, seven are symptomatic treatments tar-
geting neurotransmitter pathways with cognitive enhance-
ment (3) or neuropsychiatric (4) effects. Encenicline, a
nicotinic cognitive-enhancing agent, was put on clinical
hold by the FDA pending the review of gastrointestinal ef-
fects seen in some trial participants. Of the 17 DMTs in
phase III, 12 are small molecules, and 5 are immunother-
apies. All the immunotherapies and 8 of the 12 small mole-
cules are directed at amyloid-related targets. There are four
beta-site amyloid precursor protein cleaving enzyme
(BACE) inhibitors in phase III trials. Amyloid-targeting
agents comprise 76% of the late-stage DMT pipeline. There
is one antitau agent in phase III—TRx0237.
The mean duration of trials of symptomatic agents was
23.3 weeks; the mean duration of DMT trials was
114.1 weeks. In these phase III trials, the mean number of
subjects per arm for symptomatic trials is 392.2 and for trials
of DMT agents is 516.1.
Eighty-eight percent (32 of 36) of trials are sponsored by
the biopharma industry, 2 are jointly sponsored by NIH and
industry, and 2 are sponsored by “other” entities.
Table 1 shows the agents in phase III with their mecha-
nism of action.
2.2. Phase II
There are 45 agents in phase II of AD drug development
being assessed in 52 clinical trials. The pipeline includes 12
symptomatic cognitive-enhancing agents and three agents
addressing neuropsychiatric symptoms. There are 30
DMTs being studied in phase II drug development programs;
26 of these are small molecules and four are immunother-
apies. Amyloid-related targets comprise the mechanism of
action of nine of the 26 small molecules and all four of the
immunotherapies. Forty-three percent of phase II DMTs
have amyloid-targeting mechanisms of action. Sixteen
agents have “other mechanisms” including ten putative neu-
roprotective agents and six addressing metabolic problems.
There is one antitau agent in phase II and one stem cell pro-
gram (with two trials) in phase II of development.
Phase II trials of symptomatic agents have a mean dura-
tion of 19.1 weeks and trials of DMTs in phase II have a
mean duration of 49.5 weeks. On average, there are 67.1 sub-
jects per arm in phase II trials of symptomatic treatments and
76.9 subjects per arm in trials of DMT agents.
Of the 52 trials for the 45 agents, 29 are industry-
sponsored, four are sponsored by NIH, and 18 are sponsored
Fig. 1. Agents currently in clinical trials for AD (shape indicates stage of disease of patients in the trials; color shows the mechanism of action; location shows
phase of development and category of activity—immunotherapy, disease-modifying small molecule, symptom-reducing small molecule).
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philanthropic foundations. One trial is jointly sponsored by
NIH and industry.
Table 2 shows the agents in phase II with their mechanism
of action.2.3. Phase I
There are 24 agents in phase I AD drug-development pro-
grams. Of these, three are symptomatic agents, 13 are small
molecule DMTs, and eight are DMT immunotherapies. Five
of the 13 small molecules and seven of the eight immuno-
therapies address amyloid-related mechanisms (57% of the
DMT mechanisms). One tau-directed antibody and one
tau-related small molecule are included in the AD phase I
pipeline. Five neuroprotective agents and two metabolic
agents are being assessed.
Of the 27 trials of phase I agents, 20 are sponsored by the
biopharma industry, two are funded by NIH, one is jointly
supported by NIH and industry, and four are funded through
other mechanisms.Table 3 shows the agents in phase I with their mechanism
of action.2.4. Biomarkers
Biomarkers are playing an increasingly important role in
clinical trials of DMTs. Not all trials on clinicaltrials.gov
state if biomarkers are included in their trials or discuss
the type of biomarkers included, and we discuss the percent
of trials that describe which biomarkers are included
(Table 4). In current phase III trials, measurement of cere-
brospinal fluid (CSF) amyloid beta protein (Ab) is the
most commonly used biomarker (27.7% of trials reporting
use of biomarkers), followed by volumetric magnetic reso-
nance imaging (MRI; 25%), CSF tau, and amyloid positron
emission tomography (PET; 22.2% each), fluorodeoxyglu-
cose (FDG) PET (19.4%), plasma amyloid (8.3%), and tau
PET (2.7%). Phase II biomarkers include CSF amyloid
(25%), CSF tau (21.2%), volumetric MRI (15.4%), FDG
PET (11.5%), amyloid PET (9.6%), plasma amyloid
(5.8%), and plasma tau (3.8%).
Table 1
Agents currently in phase III of development and their mechanism of action (as of 1/4/2016)
Agent Agent mechanism class Mechanism of action Clinicaltrials.gov ID Sponsor Start date
Estimated
end date
AC-1204 Metabolic Ketogenic agent NCT01741194 Accera Mar 13 Oct 17
Aducanumab Antiamyloid Monoclonal antibody NCT02484547 Biogen Sep 15 Feb 22
NCT02477800 Biogen Aug 15 Feb 22
Albumin 1 Immunoglobulin Antiamyloid Polyclonal antibody NCT01561053 Instituto Grifols, S.A. Mar 12 Dec 16
ALZT-OP1a 1 ALZT-OP1b Antiamyloid Antiamyloid combination
(undisclosed target)
NCT02547818 AZTherapies Sep 15 Mar 18
Aripiprazole Neurotransmitter based Atypical anti-psychotic NCT02168920 Otsuka Jun 14 Jul 17
AVP-786 Neurotransmitter based Mixed transmitter effect NCT02442765 Avanir Sep 15 Jul 18
NCT02446132 Avanir Dec 15 Jul 19
AZD3293 Antiamyloid BACE inhibitor NCT02245737 AstraZeneca Sep 14 May 19
Brexpiprazole (OPC-34712) Neurotransmitter based Atypical anti-psychotic NCT01862640 Otsuka Jul 13 Jun 17
NCT01922258 Otsuka Sep 13 Jun 17
CAD106 Anti-amyloid Amyloid vaccine NCT02565511 Novartis Nov 15 Aug 23
CNP520 Anti-amyloid BACE inhibitor NCT02565511 Novartis Nov 15 Aug 23
Gantenerumab Anti-amyloid Monoclonal antibody NCT02051608 Hoffmann-La Roche Mar 14 Mar 19
NCT01224106 Hoffmann-La Roche Nov 10 Oct 20
NCT01760005* Washington University
School of Medicine
Dec 12 Dec 19
Idalopirdine (Lu AE58054) Neurotransmitter based 5-HT6 antagonist NCT02079246 H. Lundbeck A/S Apr 14 Oct 17
NCT02006654 H. Lundbeck A/S Mar 14 Mar 17
NCT02006641 H. Lundbeck A/S Feb 14 Mar 17
NCT01955161 H. Lundbeck A/S Oct 13 Oct 16
Insulin (Humulin) Metabolic Metabolic agent NCT01767909 University of Southern
California
Sep 13 Feb 17
JNJ-54861911 Anti-amyloid BACE inhibitor NCT02569398 Janssen Oct 15 May 23
Masitinib Anti-inflammatory,
neuroprotective
Tyrosine kinase inhibitor NCT01872598 AB Science Jan 12 Dec 16
MK-8931 (Verubecestat) Anti-amyloid BACE inhibitor NCT01953601 Merck Sharp & Dohme Corp. Nov 13 Mar 21
Nabilone Neurotransmitter based Cannabinoid (receptor agent) NCT02351882 Sunnybrook Health Sciences
Centre
Jan 15 Dec 17
Nilvadipine Anti-amyloid Calcium channel blocker NCT02017340 St. James’s Hospital, Ireland Oct 12 Dec 17
Pioglitazone Metabolic PPAR-gamma agonist; anti-
amyloid effect
NCT02284906 Takeda Feb 15 Apr 21
NCT01931566 Takeda Aug 13 Jul 19
RVT-101 Neurotransmitter based 5-HT6 antagonist NCT02585934 Axovant Sciences Oct 15 Oct 17
Sodium oligo-mannurarate
(GV-971)
Anti-amyloid Anti-amyloid agent NCT02293915 Shanghai Greenvalley
Pharmaceutical Co., Ltd.
Apr 14 May 17
Solanezumab Anti-amyloid Monoclonal antibody NCT02008357 Eli Lilly and Company Feb 14 Apr 20
NCT01127633 Eli Lilly and Company Dec 10 Nov 18
NCT01900665 Eli Lilly and Company Jul 13 Oct 18
NCT01760005* Washington University
School of Medicine
Dec 12 Dec 19
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This analysis of clinicaltrials.gov reveals that there are
relatively few agents in AD drug-development programs.
The high failure rate in AD drug development and the small
number of drugs being assessed suggest that the emergence
of a repertoire of AD agents that could be tailored to fit the
individual needs of patients is unlikely. The small number of
agents in phase I is especially concerning as this phase is the
major source of drugs for later stage development. A few re-
purposed agents can enter at phase II or phase III, but these
agents generally have limited patent lives or limited intellec-
tual property opportunities and do not comprise a major
source of new candidate compounds [8]. Likewise, immuno-
therapies often begin in phase I/phase II with patients diag-
nosed with AD to avoid the risk of permanently altering the
immune system of normal volunteers but, as can be seen,
there are only a few such agents entering the drug-
development pipeline. Overall, the AD ecosystem of AD
drug development must be altered to yield more targets
and more candidate therapies if a robust pipeline of therapies
is to be established.
Other reviews of AD drug development have led to
similar conclusions as those presented here. The comprehen-
sive 2010 review byMangialasche et al. [9] showed that new
approaches to cholinergic therapy and many antiamyloid tri-
als were being pursued. There were more agents directed to-
ward tau-related targets in the 2010 pipeline review; most of
these have since failed. Fig. 1 is similar to the visualization
approach used by Mangialasche et al. [9] and can be used to
compare changes over a 6-year period. Similarly, Cummings
et al [3] found—using a similar strategy to that used in the
current review—that there were relatively few drugs being
assessed and that the overall failure rate for AD drug devel-
opment was a dramatic 99.6%. They also noted that no new
novel drugs for AD had been approved since 2003.
We compared AD drug development with oncology drug
development to provide a perspective on the observed
numbers. In the 2014–2015 period, 135 trials were registered
for AD, whereas 4976 trials were registered for cancer (these
figures were generated from clinicaltrials.gov using the same
search terms as used in the reviewed AD trials and agents).
This indicates that the number of agents in trials is much
larger for cancer than for AD and the likelihood of finding
effective therapies is greater. This disparity likely reflects
several influences including the greater success of rate of can-
cer drug development (19.8% of development programs suc-
ceed in cancer vs less than 1 percent of AD drugs [3,10]).
Thirty-one percent of FDA new drug approvals for 2015
were for oncology agents [11]. The low success rate of AD
drug development discourages pharmaceutical companies
from pursuing research in this area and reduces the enthu-
siasm of venture capitalists for investing in biotechnology
companies whose products address AD-related targets. As a
result, fewer targets are identified, and fewer candidate agents
discovered and developed. The biological understanding of
Table 2
Agents currently in phase II of AD drug development and their mechanism of action (as of 1/4/2016)
Agent Agent mechanism class Mechanism of action Clinicaltrials.gov ID Sponsor Start date
Estimated
end date
Adenosine triphosphate Antiamyloid Inhibits amyloid misfolding and
toxicity
NCT02279511 Fundacio Clınic per la Recerca
Biomedica
Nov 14 Nov 16
ANAVEX 2-73 Neuroprotective Sigma-1 receptor agonist NCT02244541 Anavex Life Sciences Corp. Dec 14 Oct 16
Atomoxetine Antiamyloid Adrenergic uptake inhibitor NCT01522404 Emory University Mar 12 Dec 17
AZD0530 (saracatinib) Antiamyloid Kinase inhibitor NCT02167256 Yale University Dec 14 Dec 16
BAN2401 Antiamyloid Monoclonal antibody NCT01767311 Eisai Dec 12 Jul 18
Benfotiamine Metabolic Antioxidant NCT02292238 Burke Medical Research Institute Nov 14 Nov 19
BI 409306 Neuroprotective PDE9 inhibitor NCT02240693 Boehringer Ingelheim Jan 15 Jun 17
NCT02337907 Boehringer Ingelheim Jan 15 May 17
Byrostatin 1 Neuroprotective Protein kinase C inhibitor NCT02431468 Neurotrope Bioscience Jul 15 Apr 17
Cilostazol Neuroprotective PDE3 antagonist NCT02491268 National Cerebral and Cardiovascular
Center
Jul 15 Jul 18
CNP520 Antiamyloid BACE inhibitor NCT02576639 Novartis Aug 15 Mar 16
CPC-201 Neurotransmitter based Cholinesterase inhibitor 1 peripheral
cholinergic antagonist
NCT02185053 Chase Pharmaceuticals Corporation Jul 14 Mar 16
NCT02434666 Chase Pharmaceuticals Corporation Jan 15 Jul 16
Crenezumab Anti-amyloid Monoclonal antibody NCT01998841 Genentech Dec 13 Sep 20
DAOIB Neurotransmitter based NMDA enhancer NCT02103673 Chang Gung Memorial Hospital Feb 14 Sep 16
NCT02239003 Chang Gung Memorial Hospital Jan 12 Jul 16
E2609 Anti-amyloid BACE inhibitor NCT02322021 Eisai Nov 14 Jul 19
Exenatide Metabolic Glucagon-like peptide 1 receptor
agonist
NCT01255163 National Institute on Aging (NIA) Nov 10 Dec 18
Formoterol A&B Neuroprotective Beta-2 adrenergic receptor agonist NCT02500784 Palo Alto Veterans Institute for
Research
Jan 15 Jul 16
hUCB-MSCs Neuroprotective Stem cell therapy NCT02054208 Medipost Co Feb 14 Feb 18
NCT01547689 Affiliated Hospital to Academy of
Military Medical Sciences,
Beijing, China
Mar 12 Dec 16
Insulin detemir Metabolic Insulin NCT01595646 University of Washington Nov 11 Sep 15
Insulin glulisine Metabolic Insulin NCT02503501 HealthPartners Institute for Education
and Research
Aug 15 Sep 17
JNJ-54861911 Anti-amyloid BACE inhibitor NCT02406027 Janssen Jul 15 Jun 24
NCT02260674 Janssen Nov 14 Jun 16
Levetiracetam Neurotransmitter based Anticonvulsant NCT02002819 University of California, San
Francisco
Jun 14 Jun 17
Liraglutide Metabolic Glucagon-like peptide 1 receptor
agonist
NCT01843075 Imperial College London Jan 14 Jan 17
Lithium Neurotransmitter based Ion channel modulator NCT02129348 New York State Psychiatric Institute Jun 14 Apr 19
Metformin Metabolic Insulin sensitizer NCT01965756 University of Pennsylvania Jan 13 Dec 16
Methylene Blue Anti-tau Tau inhibitor; neuronal stimulant NCT02380573 University of Texas Health Science
Center at San Antonio
Jul 15 Jul 18
MK-7622 Neurotransmitter based Muscarinic agonist NCT01852110 Merck Oct 13 Apr 20
MK-8931 Anti-amyloid BACE inhibitor NCT01739348 Merck Nov 12 Jul 19
NewGam 10% IVIG Anti-amyloid Polyclonal antibody NCT01300728 Sutter Health Jan 11 Nov 17
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ORM-12741 Neurotransmitter based Alpha-2c adrenergic receptor
antagonist
NCT02471196 Orion Corporation Jun 15 Feb 17
PF-05212377 (SAM 760) Neurotransmitter based 5-HT6 receptor antagonist NCT01712074 Pfizer Nov 12 Dec 15
Pimavanserin tartrate Neurotransmitter based 5-HT2A inverse agonist NCT02035553 Acadia Nov 13 Jun 16
Piromelatine Neurotransmitter based Melatonin receptor agonist; 5-HT 1A
and 1D receptor agonist
NCT02615002 Neurim Pharmaceuticals Nov 15 Dec 17
PQ912 Anti-amyloid, anti-inflammatory Glutaminyl-peptide cyclotransferase
inhibitor
NCT02389413 Probiodrug AG Mar 15 Oct 16
PXT00864 Neurotransmitter based Combination of acamprosate and
baclofen
NCT02361242 Pharnext, SAS Jun 13 Dec 15
Rasagiline Neuroprotective Monoamine oxidase B inhibitor NCT02359552 The Cleveland Clinic Feb 15 Dec 16
Riluzole Neuroprotective Glutamate receptor antagonist;
glutamate release inhibitor
NCT01703117 Rockefeller University Apr 13 Nov 17
RPh201 Neuroprotective G-protein coupled receptor antagonist NCT01513967 Regenera Pharma Jan 12 Dec 16
S47445 (formerly CX1632) Neurotransmitter based AMPA receptor agonist; nerve growth
factor stimulant
NCT02626572 Institut de Recherches Internationales
Servier
Feb 15 Sep 17
Sagramostim (GM-CSF) Anti-amyloid Granulocyte colony stimulator;
amyloid removal
NCT01409915 University of Colorado, Denver Mar 11 Jul 16
Sembragiline (RO4602522) Neurotransmitter based Monoamine oxidase B inhibitor NCT01677754 Hoffmann-La Roche Nov 12 Jun 15
Simvastatin 1 L-
Arginine 1 Tetrahydrobiopterin
Neuroprotective HMG-CoA reductase inhibitor and
antioxidant
NCT01439555 University of Massachusetts,
Worcester
Nov 11 Dec 16
SUVN-502 Neurotransmitter based 5-HT6 antagonist NCT02580305 Suven Life Sciences Sep 15 Jun 17
T-817 MA Neuroprotective Neurotrophic agent NCT02079909 Toyama Mar 14 Mar 17
Telmisartan Neuroprotective PPAR-gamma agonist NCT02085265 Sunnybrook Health Sciences Centre Mar 14 Aug 18
UB-311 Anti-amyloid Monoclonal antibody NCT02551809 United Neuroscience Oct 15 Jan 18
VX-745 Neuroprotective P38 mitogen-activated protein kinase
inhibitor
NCT02423200 EIP Pharma Apr 15 Jan 16
NCT02423122 EIP Pharma Apr 15 Sep 16
Abbreviations: AMPA, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; BACE, beta-site amyloid precursor protein cleaving enzyme. GM-CSF, granulocyte-macrophage colony-stimulating factor;
HMG-CoA, 3-hydroxy-3-methylglutaryl-coenzyme; hUCB-MSCs, human umbilical cord-derived mesenchymal stem cells; IVIG, intravenous immunoglobulin; NMDA, N-methyl-D-aspartate; PDE, phospho-
diesterase; PPAR, peroxisome proliferator-activated receptor.
NOTE. Forty-six agents in 52 phase II clinical trials currently ongoing (active, not recruiting and active, recruiting) as of January 4, 2016 according to clinicaltrials.gov.
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Table 3
Agents currently in phase I of development and their mechanism of action (as of 1/4/2016)
Agent Agent mechanism class Mechanism of action Clinicaltrials.gov ID Sponsor Start date
Estimated
end date
AADvac1 Anti-tau Monoclonal antibody directed at Tau epitope NCT02031198 Axon Neuroscience Jan 14 Sep 17
ABT-957 Neuroprotective Calpain inhibitor NCT02220738 AbbVie Sep 14 Jun 16
NCT02573740 AbbVie Nov 15 Nov 16
Aducanumab Anti-amyloid Monoclonal antibody NCT01677572 Biogen Oct 12 Oct 19
NCT02434718 Biogen May 15 Jul 17
Allopregnanolone injection Neuroprotective GABA receptor modulator NCT02221622 University of Southern California Aug 14 Mar 17
BI 409306 Neurotransmitter based PDE 9A inhibitor NCT02392468 Boehringer Ingelheim Apr 15 Oct 16
Bisnorcymserine (BNC) Neurotransmitter based Butyrylcholinesterase inhibitor NCT01747213 National Institute on Aging (NIA) Nov 12 Jul 17
Crenezumab Anti-amyloid Monoclonal antibody NCT02353598 Genentech Feb 15 Sep 17
CT1812 Anti-amyloid Sigma-2 receptor modulator; reduces
amyloid toxicity
NCT02570997 Cognition Therapeutics Sep 15 Jun 16
GC021109 Anti-inflammatory,
neuroprotective
Anti-inflammatory NCT02386306 GliaCure Feb 15 Oct 15
Insulin Aspart Intranasal Metabolic Insulin NCT02462161 Wake Forest School of Medicine May 15 Dec 16
JNJ-54861911 Anti-amyloid BACE inhibitor NCT02360657 Janssen Feb 15 Sep 15
KHK6640 Anti-amyloid Amyloid aggregation inhibitor NCT02127476 Kyowa Hakko Kirin Pharma Jul 14 Feb 17
NCT02377713 Kyowa Hakko Kirin Pharma Mar 15 Dec 16
Lorazepam Neurotransmitter based Benzodiazepam NCT01780519 Mayo Clinic Jan 13 Sep 16
Lu AF20513 Anti-amyloid Monoclonal antibody NCT02388152 H. Lundbeck A/S Mar 15 Dec 16
LY2599666 1 Solanezumab Anti-amyloid Monoclonal antibody combination NCT02614131 Eli Lilly and Company Dec 15 Jul 17
LY3002813 Anti-amyloid Monoclonal antibody NCT01837641 Eli Lilly and Company May 13 Sep 16
LY3202626 Anti-amyloid Undisclosed mechanism NCT02323334 Eli Lilly and Company Dec 14 Feb 16
MEDI1814 Anti-amyloid Monoclonal antibody NCT02036645 AstraZeneca Feb 14 Oct 16
NGP 555 Anti-amyloid Gamma-secretase modulator NCT02534480 NeuroGenetic Pharmaceuticals Mar 15 Nov 15
Oxaloacetate Metabolic Mitochondrial enhancer NCT02593318 University of Kansas Medical Center Oct 15 Oct 17
PF-06751979 Anti-amyloid Undisclosed mechanism NCT02509117 Pfizer Jul 15 Jul 16
S-Equol Neuroprotective Estrogen receptor beta agonist NCT02142777 University of Kansas Medical Center Jul 14 Dec 16
Telmisartan Neuroprotective PPAR-gamma agonist NCT02471833 Emory University Apr 15 Mar 18
TPI-287 Anti-tau Microtubule protein modulator NCT01953705 University of California, San Francisco May 14 Mar 19
Abbreviations: BACE 5 beta-site amyloid precursor protein cleaving enzyme; GABA 5 gamma-aminobutyric acid; PDE 5 phosphodiesterase; PPAR 5 peroxisome proliferator-activated receptor.
NOTE. Twenty-four agents in 27 phase I clinical trials currently ongoing (active, not recruiting, and active, recruiting) as of January 4, 2016, according to clinicaltrials.gov.
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Table 4
Percent of trials with specific biomarkers included (this calculation is based
on the number of trials in which the inclusion of biomarkers is described)
Biomarker
% of trials
Phase III Phase II
1. CSF amyloid 27.7 25
2. CSF tau 22.2 21.1
3. FDG-PET 19.4 11.5
4. vMRI 25 15.3
5. Plasma amyloid 8.3 5.7
6. Plasma tau 0 3.8
7. Amyloid PET 22.2 9.6
8. Tau PET 2.7 0
J. Cummings et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 2 (2016) 222-232230cancer has identified more putative targets. Greater insight
into AD pathophysiology may lead to more target identifica-
tion and more opportunities to develop mechanistically
informed treatments.
The AD drug-development pipeline has amyloid beta-
protein production or removal as it major focus. Across all
phases, 56% of DMTs have an amyloid-related target.
Monoclonal antibodies and BACE inhibitors comprise the
two most developed pathways in the current pipeline. Mono-
clonal antibody approaches have instituted two major
changes in drug development based on experiences with
the failure of bapineuzumab: (1) patient populations with
more mild disease are now the focus of trials [12]; (2) amy-
loid imaging or CSFAb measures are performed at baseline
to insure that patients have the target pathology for antiamy-
loid therapies [13,14]. BACE inhibitors have included
measures of CSF Ab to demonstrate target engagement
and show that the putative goal of reduction is being
achieved [15]. Demonstration of target engagement early
in the development process makes it more likely—without
proving—that clinical benefits may follow long-term ther-
apy [16].
Tau is a relatively unexploited target with only four
agents in the pipeline devoted to tau-related pathophysi-
ology. The availability of tau imaging and the consistent re-
lationships shown between tau signals on imaging and the
clinical state of the individual indicate that tau is an impor-
tant target for drug development and that tau imaging may
serve as a useful biomarker to help guide drug development
[17–20]. Tau protein is being targeted in trials of
experimental therapies for tauopathies including
frontotemporal dementia and progressive supranuclear
palsy, and learnings from these trials may inform treatment
of tau pathology in AD.
Thirty-eight percent of DMTs are small molecule agents
that address neuroprotection or metabolic targets such as in-
sulin resistance or PPAR-gamma–related mechanisms.
These approaches are more well represented in phase II
than phase III and suggest that the repertoire of targets is
broadening for agents in the AD pipeline.Symptomatic agents represent an important part of the
AD drug-development pipeline. Improvement in cognitive
and behavioral symptoms is a major goal of treatment and
is achieved only partially by current therapies. There are
25 symptomatic cognitive enhancers or neuropsychiatric
agents in the current pipeline comprising 27% of the entire
drug-development pipeline. Symptomatic treatments are
especially well represented in phase II where they comprise
33% of all agents at that stage of development. These agents
enhance cholinergic signaling or capitalize on noncholiner-
gic serotonergic, sigma-1, phosphodiesterase, or N-methyl-
D-asparate (NMDA) mechanisms.
There is increasing recognition that combination thera-
pies may be warranted to address the complex biology of
AD [21]. Combinations have found success in other complex
diseases such as cancer, tuberculosis, and human immunode-
ficiency virus infections. There are few examples in the AD
pipeline of combination of agents in trials; ALZT-OP1a/1b
is a combination approach at phase III, simvastatin/l-
arginine/tetrahydrobiopterin is being assessed at phase II;
and LY2599666 plus solanezumab is being tested in phase
I. In addition to these pharmacodynamics combinations,
AVP-786 is a pharmacokinetic combination of dextrome-
thorphan and the CYP2D6 inhibitor, quinidine, used to
elevate levels of dextromethorphan. Overall, combinations
comprise a limited aspect of the AD drug-development pipe-
line and represent an important future direction of drug
development.
Currently, DMTs spend relatively little time in phase II
(average 49 weeks) and involve a small number of patients
per trial arm (average 67). Given the 100% failure rate of
DMTs in phase III, more thorough exploration of these
agents in phase II may benefit drug-development programs
and the likelihood of phase III success.
Biomarkers play an increasingly important role in AD
drug development. The demonstration that approximately
25% of patients included in trials of clinical-diagnosed AD
do not have elevated levels of brain amyloid when studied
with amyloid imaging indicated that use of biomarkers
was critical in identifying a population with the target pa-
thology in trials of antiamyloid agents and that have an accu-
rate diagnosis for inclusion of trials of other agents [13,14].
Nearly, all current trials of antiamyloid agents require
positive amyloid imaging at baseline to insure accurate
diagnosis and include amyloid imaging as an outcome to
determine the effect of the therapeutic intervention on the
brain plaque burden. Target engagement biomarkers are
now more commonly used in drug-development programs
such as those for BACE inhibitors to show that a biological
effect has been achieved and that clinical effects could
reasonably be expected. CSF measurements of amyloid
and tau, volumetric MRI, and amyloid PETare used approx-
imately equally commonly in DMT programs; no consensus
on a single biomarker or combination of biomarkers as
J. Cummings et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 2 (2016) 222-232 231optimal to meet regulatory expectations for biomarker data
has emerged.
Of trials across all phases of AD drug development, 74%
are completely or partially sponsored by the biopharmaceu-
tical industry. Given the prominent role of industry in AD
drug development, legislative incentives to attract the phar-
maceutical and biotechnology industries to AD may be one
of the means of enhancing the number of candidate agents
entering the AD pipeline. Increased federal funding to
augment the small number of trial sponsored by NIH (9%
with total or partial NIH funding) might also enhance the
pipeline. Funding for basic science through NIH or venture
capital support of biotechnology companies is needed to
identify new targets and generate new candidate therapies.
Similarly, new strategies in drug development including
more emphasis on demonstrating target engagement in early
stage development and use of adaptive designs to support
clinical trials decision making may accelerate the drug
development process and decrease the number of late-
stage failures of agents in the pipeline.
This analysis is based on a review of clinicaltrials.gov
and is subject to the limitations of that database. While in-
clusive of all trials in the United States and many non-US
countries, it may not include all trials being conducted in
other countries and the list of drugs we discuss may not be
comprehensive from an international perspective. In addi-
tion, not all phase I trials are included on clinicaltrials.gov,
especially when they are conducted in non-US phase I
units, and we may underestimate the total number of
agents being assessed in phase I. There is sometimes a
lag in listing trials on clinicaltrials.gov, and the lists
included here may not be fully comprehensive for the
time window assessed. These limitations will affect some
details of the analysis but not the overall view of the land-
scape of AD drug development.
In summary, the AD drug-development pipeline is
modest in size and strikingly smaller than very active
areas of experimental therapeutics such as cancer. The
phase I candidate pool is particularly small and bodes
poorly for a compelling set of agents to be advanced to
phase II and III. Amyloid is the most common pharmaceu-
tical target, reflecting the greater understanding of the
pathophysiology of this peptide. Symptomatic agents are
making progress toward treatment of both cognitive and
behavioral symptoms of AD. Biomarkers are being inte-
grated into DMT development programs. Every source
of compounds including academic medical centers, NIH,
philanthropic funders, biotechnology, and pharmaceutical
companies should be attracted to AD drug development
to create a larger pipeline and a greater chance of success
of AD drug development.Acknowledgments
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1. Systematic Review: Drug development for Alz-
heimer’s disease (AD) proceeds through three phases
(I, II, III). By assessing the number of agents in each
phase as recorded on clinicaltrials.gov, one can deter-
mine current AD drug development activity to assess
howmany agents are being studied, the success of the
research, and how the number of new drugs can be
increased.
2. Interpretation: Our data show that there are 93 drugs
in development for treatment of AD. There are more
drugs in phase II (45) than in phase III (24) or phase I
(24). The small number of phase I compounds sug-
gest that there is insufficient drug discovery activity
to supply new agents for testing in clinical trials.
3. Future directions: This review of the AD drug-
development pipeline provides insight into the state
of AD drug development and encourages review of
how best to amplify the drug discovery/development
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